Accelerated versus classical hepatitis B virus vaccination programs in healthcare workers accelerated vs. classical HBV vaccination

WOS: 000242137900010PubMed ID: 17072271The aim of this study was to compare the efficacy of a standard hepatitis B virus vaccination program (day 0-30-60) with an accelerated vaccination program (day 0-10-21) in healthy healthcare workers. Participants were randomly assigned to a classical (group 1, days 0, 30, and 60) or an accelerated vaccination program (group 2, days 0, 10, and 21). The vaccine used was 20 mu g recombinant hepatitis B vaccine (recombinant hepatitis B vaccine derived from yeast cells, Engerix B, Smith Cline Beachum). HBV markers were re-examined for the emergence of anti-HBsAg and also to detect the development of a possible acute HBV infection one, two, and three months after the last dose of vaccine. Anti-HBsAg titers > 10 mIU/1 were accepted as protective. The seroprotection rates were similar one, two, and three months after the last dose of vaccine in both groups. Anti-HBsAg titers in group 1 were higher than in group 2 two and three months after the last dose of vaccination (p < 0.05). Our data indicate that the accelerated HBV vaccination program was as effective as the classical vaccination program

Diabetic Extremity Infections: Our Clinical Experiences

Between April’93 & March’96, we follewed 93 patients (68 men & 33 women) who have 101 extremity infections in Internal Medicine Section, Infectious Diseases Unit. Among them one patient three times and six patients two times was followed. 93 infections diagnosed in lower extremities and 8 in upper. 39 (38.6%) of them was osteomyelitis and 62 (61.4%) wus soft tissue infection. Amputation was done in 17 (16.8%) patients because of late admission and gangrene 28 (27.7%) bacterial growth detected in aspiration cultures. The most frequent isolate was S.aureus (35.6%)